[Multiple sclerosis. New therapeutic strategies in the experimental stage].
Extensive research in the field of multiple sclerosis (MS) has lead to a preliminary pathogenetic concept without solving the etiopathogenesis. According to animal experiments and human in vitro studies MS is a T cell-mediated autoimmune disease. Experimental therapeutical strategies are aiming at the inhibition of T cell activation, transmigration through the blood brain barrier and local inflammation and demyelination. Several substances are already being tested in clinical studies with magnetic resonance imaging as a tool to quantify inflammatory lesions and to shorten the study course. This review will give a summary about actual experimental therapies resulting from the current pathogenetic concept.
Zipp
F
F
Neurologische Klinik, Eberhard-Karls-Universität Tübingen.
Sommer
N
N
Rösener
M
M
Dichgans
J
J
Martin
R
R
D000818:Animals; D001812:Blood-Brain Barrier / Q000276:immunology; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D008213:Lymphocyte Activation / Q000276:immunology; D009103:Multiple Sclerosis / Q000276:immunology / Q000628:therapy*; D009413:Nerve Fibers, Myelinated / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology; D016896:Treatment Outcome